Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study
Primary result · Mean body weight change from baselineResult — go to the resultMixed model repeated measures difference −3.6 % 95% CI −4.6% to −2.6%Authors' conclusion
Beinaglutide combined with lifestyle intervention resulted in significant and clinically meaningful weight reduction with good tolerance in non-diabetic Chinese individuals with overweight or obesity.
Study context
- Population
- Non-diabetic Chinese adults with BMI ≥28 kg/m² (obesity) or 24–27.9 kg/m² (overweight) with weight-related complicationsrandomized 2:1
- Participants
- 427 adults
- Comparison
- Beinaglutide 0.2 mg SC thrice daily vs placebo, as adjunct to lifestyle intervention, 16 weeks
- Beinaglutiden = 282
- Placebon = 138reference
- Primary endpoint
- Co-primary: body weight change and proportion with weight reduction ≥5%
- Follow-up
- Week 16
Methodological detailsmulticentre, double-blind, placebo-controlled
- Multicentre
- Double-blind
- Placebo-controlled
Primary result
Mean body weight change from baseline
Mixed model repeated measures difference
−3.6 %
95% CI −4.6% to −2.6%
P < 0.0001
Change by group
Beinaglutide
−6.0
mean · %
Placebo
−2.4
mean · %
As reported in the abstract
Further findings
Co-primary: weight reduction ≥5% · week 16
OR 4.4 · P < 0.0001
Weight reduction ≥10% · week 16
OR 5.5 · P < 0.0001
| Outcome | Beinaglutide | Placebo | Difference (cm) | P value |
|---|---|---|---|---|
| Waist circumference reductionGreater reduction with Beinaglutide | −1.81 | P < 0.01 | ||
| Weight regain rate · 12 weeks after beinaglutide treatment | 0.78% | — not stated in the abstract |
— not stated in the abstract
Safety
Nausea (transient, mild-to-moderate); most common AE with beinaglutide
Discontinuation due to AEs
Pancreatitis or increased resting heart rate
- Not observed with beinaglutide
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →